We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 27, 2021

Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane Impacts Survival of HER2-Negative Breast Cancer

Anticancer Research

 

Additional Info

Anticancer Research
Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: The JONIE1 Study
Anticancer Res. 2021 Feb 01;41(2)1063-1068, A Yamada, K Nakazawa, K Akazawa, K Narui, I Endo, Y Hasegawa, N Kohno, T Ishikawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading